TRPV-1-mediated elimination of residual iPS cells in bioengineered cardiac cell sheet tissues
- PMID: 26888607
- PMCID: PMC4757885
- DOI: 10.1038/srep21747
TRPV-1-mediated elimination of residual iPS cells in bioengineered cardiac cell sheet tissues
Abstract
The development of a suitable strategy for eliminating remaining undifferentiated cells is indispensable for the use of human-induced pluripotent stem (iPS) cell-derived cells in regenerative medicine. Here, we show for the first time that TRPV-1 activation through transient culture at 42 °C in combination with agonists is a simple and useful strategy to eliminate iPS cells from bioengineered cardiac cell sheet tissues. When human iPS cells were cultured at 42 °C, almost all cells disappeared by 48 hours through apoptosis. However, iPS cell-derived cardiomyocytes and fibroblasts maintained transcriptional and protein expression levels, and cardiac cell sheets were fabricated after reducing the temperature. TRPV-1 expression in iPS cells was upregulated at 42 °C, and iPS cell death at 42 °C was TRPV-1-dependent. Furthermore, TRPV-1 activation through thermal or agonist treatment eliminated iPS cells in cardiac tissues for a final concentration of 0.4% iPS cell contamination. These findings suggest that the difference in tolerance to TRPV-1 activation between iPS cells and iPS cell-derived cardiac cells could be exploited to eliminate remaining iPS cells in bioengineered cell sheet tissues, which will further reduce the risk of tumour formation.
Conflict of interest statement
There is potential competing interest. Teruo Okano is a founder and a member of the board of CellSeed Inc., which has licenses for certain cell sheet-related technologies and patents from Tokyo Women’s Medical University. Teruo Okano and Tatsuya Shimizu are stake holders of CellSeed Inc. Tokyo Women’s Medical University receives research funds from CellSeed Inc. Teruo Okano, Tatsuya Shimizu, and Katsuhisa Matsuura are inventors of bioreactor systems.
Figures
References
-
- Nishida K. et al.. Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. N Engl J Med 351, 1187–1196 (2004). - PubMed
-
- Sawa Y. et al.. Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM: report of a case. Surg Today 42, 181–184 (2012). - PubMed
-
- Ohki T. et al.. Prevention of esophageal stricture after endoscopic submucosal dissection using tissue-engineered cell sheets. Gastroenterology 143, 582–588 e582 (2012). - PubMed
-
- Takahashi K. et al.. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
